Expert Interview
Sharing your thoughts on the potential of Fractyl Health's lead drug candidate Rejuva, an adeno-associated virus (AAV)-based GLP-1 pancreatic gene therapy.
Ticker(s): GUTS, NVO, LLY- Retired from active practice in Sept 2021 and now teach in the clinics only
- 800-900 patients with type 1 diabetes at time of retirement and directed the clinical diabetes center at Washington University School of medicine.
- Professor of medicine, Division of Endocrinology at Washington University
- Former director of the Washington University diabetes center at Barnes-Jewish Hospital
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
